XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisition of Pionyr Therapeutics - Schedule of Fair Value of Equity Issued and Consideration Transferred (Details) - Pionyr Immunotherapeutics, Inc
$ in Thousands
Aug. 04, 2023
USD ($)
Business Acquisition [Line Items]  
Total $ 48,017
Series A Preferred Stock  
Business Acquisition [Line Items]  
Issuance of stock 32,837
Common Stock  
Business Acquisition [Line Items]  
Issuance of stock 14,236
Restricted Stock Units ("RSUs") and Stock Options  
Business Acquisition [Line Items]  
Cash consideration paid 738
Unaccredited Stockholders  
Business Acquisition [Line Items]  
Cash consideration paid $ 206